According to a report in the Wall Street Journal, a court in Cologne, Germany has issued a preliminary injunction preventing Sandoz from marketing its AirFluSal Forspiro in Germany. GlaxoSmithKline had argued that Sandoz’s salmeterol/fluticasone DPI presented unfair competition to GSK’s Advair because the purple color of the Forspiro inhaler would lead consumers to confuse the product with Advair Diskus.
Sandoz announced that it had German marketing authorization for AirFluSal Forspiro on January 13, 2014. The injunction was reportedly issued on February 6.
Read the WSJ article.
